Retour
Prix Genmab A/S (GMAB)
Graphique du cours de l'action GMAB
GMAB Gagner
Genmab A/S
$31.33
-2.85%
$-0.92
À la fermeture : Jan 20, 16:00:00 GMT-5
$31.4
0.22%
$0.07
Post-Marché: Jan 20, 20:00:00 GMT-5
Statistiques clés
Clôture préc.
$32.25
Prix d'ouverture
$31.38
Plage de la journée
$31.05 - $31.68
Plage de 52 semaines
$17.23 - $35.43
Volume
2.7M
Volume moyen
1.8M
BPA (TTM)
2.29
Rendement en dividend
--
Capitalisation boursière
$19.3B
Qu’est-ce que Genmab A/S ?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved